Key result
Human MIKO-1 significantly reduced lung fibrosis scores, collagen content, and inflammatory gene expression compared to bleomycin alone in a mouse model of interstitial lung disease.
Why the study?
Interstitial lung disease is a life-threatening condition causing respiratory failure, but the efficiency of current therapies remains limited.
Does human MIKO-1 reduce lung fibrosis in a mouse model of bleomycin-induced interstitial lung disease?
Does human MIKO-1 reduce lung fibrosis in a mouse model of bleomycin-induced interstitial lung disease?
Human MIKO-1 reduces lung fibrosis and suppresses macrophage polarization to M2 predominance in a mouse model of bleomycin-induced interstitial lung disease, suggesting potential as a therapeutic candidate.
Answers are grounded in this paper and cite their sources.
Loading...
Hypothesis-generating for macrophage-targeted therapy in ILD; leaves open translation to human trials.
Although interstitial lung disease (ILD) is a life-threatening pathological condition that causes respiratory failure, the efficiency of current therapies is limited. This study aimed to investigate the effects of human MIKO-1 (hMIKO-1), a hybrid protein that suppresses the abnormal activation of macrophages, on murine macrophage function and its therapeutic effect in a mouse model of bleomycin-induced ILD (BLM-ILD). To this end, the phenotype of thioglycolate-induced murine peritoneal macrophages co-cultured with hMIKO-1 was examined. The mice were assigned to normal, BLM-alone, or BLM + hMIKO-1 groups, and hMIKO-1 (0.1 mg/mouse) was administered intraperitoneally from day 0 to 14. The mice were sacrificed on day 28, and their lungs were evaluated by histological examination, collagen content, and gene expression levels. hMIKO-1 suppressed the polarization of murine macrophages to M2 predominance in vitro. The fibrosis score of lung pathology and lung collagen content of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. The expression levels of TNF-α, IL-6, IL-1β, F4/80, and TIMP-1 in the lungs of the BLM + hMIKO-1 group were significantly lower than those in the BLM-alone group. These findings indicate that hMIKO-1 reduces lung fibrosis and may be a future therapeutic candidate for ILD treatment.
Kotani et al. (2022) studied Bleomycin-induced interstitial lung disease. human MIKO-1 (hMIKO-1) vs. Bleomycin alone was evaluated on Lung fibrosis score and lung collagen content. Human MIKO-1 significantly reduced lung fibrosis scores, collagen content, and inflammatory gene expression compared to bleomycin alone in a mouse model of interstitial lung disease.